Context Therapeutics reports FY2021 net loss of $10.5M; cash $49.7M into 2024

Context Therapeutics Inc.

Cash, equivalents and restricted cash $49.7M at Dec 31, 2021 (vs $0.3M in 2020); expected to fund operations into 2024.
Net loss of $10.5M for FY2021 vs net income of $6.6M in 2020; R&D expenses $3.8M, G&A $3.6M.
Closed $31.25M private placement in Dec 2021; $28.75M IPO earlier; pipeline includes three Phase 2 ONA-XR trials and CLDN6 bsAb candidate selection in 2022.
Appointed Christopher Beck as SVP Operations and Mark Fletcher as VP R&D in Jan 2022.
Preliminary data expected mid-2022 from first-line metastatic breast cancer and recurrent endometrial cancer trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.